| Nifedipine | acute coronary syndrome, in all type of patients | vs metoprolol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| HINT (nifedipine vs metoprolol), 1988 | nifedipine | metoprolol | patients with unstable angina not pretreated with a beta-blocker and of nifedipine |
| |
| Nifedipine | acute myocardial infarction, in acute short term and post MI studies | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.99 [0.46 2.12] | p=1.00 | 0 | 207 | 2 | Muller, Gordon, | | cardiac death | no data | | All cause death | 1.07 [0.85 1.35] | p=1.00 | 0 | 1999 | 3 | Muller, Gordon, MI study group, |
| Trial | Studied treatment | Control | Patients |
|---|
| Muller, 1984 | Nifedipine 20mgx6 | | | | Gordon, 1984 | Nifedipine 10 mgx4 | | | | MI study group, 1979 | Nifedipine 3-4x60mg | | |
| |
| Nifedipine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 1.00 [0.90 1.11] | p=1.00 | 0 | 7041 | 10 | Eisenberg, Bradagan, Jaffe, Gottlieb, Erbel, SPRINT II, Loogna, TRENT (Wilcox), Walker, Sirnes, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.94 1.29] | p=1.00 | 0 | 9059 | 10 | Eisenberg, Bradagan, Jaffe, Gottlieb, Erbel, SPRINT I, SPRINT II, TRENT (Wilcox), Walker, Sirnes, |
| Trial | Studied treatment | Control | Patients |
|---|
| Eisenberg, 1985 | Nifedipine 20mgx4 | placebo | patients with nontransmural myocardial infarction | | Bradagan, 1986 | Nifedipine 10mgx4 | placebo | patients with suspected acute myocardial infarction within 6hrs | | Jaffe, 1987 | Nifedipine 6x20mg | placebo | patients with acute myocardial infarction | | Gottlieb, 1988 | Nifedipine 10 to 30mgx4 | placebo | | | Erbel, 1988 | Nifedipine 20mgx3 | placebo | patients with acute myocardial infarction | | SPRINT I, 1988 | Nifedipine 10mgx3 | placebo | patient surviving MI 7 and 21 days after admission | | SPRINT II, 1993 | Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months | placebo | men and women with suspected acute MI | | Loogna, 1985 | Nifedipine 4x10mg | placebo | patients with acute myocardial infarction within 6 h from onset of symptoms | | TRENT (Wilcox), 1986 | Nifedipine 4x10mg | placebo | patients with suspected myocardial infarction | | Walker, 1988 | Nifedipine 6x10mg for 48hrs | placebo | patients with suspected myocardial infarction within six hours from the onset of chest pain | | Sirnes, 1984 | Nifedipine 5x10mg | placebo | patients with suspected acute myocardial infarction |
| |
| Nifedipine | acute myocardial infarction, in acute (short term) treatment | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.99 [0.46 2.12] | p=1.00 | 0 | 207 | 2 | Muller, Gordon, | | cardiac death | no data | | All cause death | 2.81 [0.64 12.40] | p=1.00 | 0 | 207 | 2 | Muller, Gordon, |
| Trial | Studied treatment | Control | Patients |
|---|
| Muller, 1984 | Nifedipine 20mgx6 | | | | Gordon, 1984 | Nifedipine 10 mgx4 | | |
| |
| Nifedipine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 1.00 [0.89 1.12] | p=1.00 | 0 | 5683 | 9 | Eisenberg, Bradagan, Jaffe, Gottlieb, Erbel, Loogna, TRENT (Wilcox), Walker, Sirnes, | | cardiac death | no data | | All cause death | 1.11 [0.89 1.37] | p=1.00 | 0 | 5425 | 8 | Eisenberg, Bradagan, Jaffe, Gottlieb, Erbel, TRENT (Wilcox), Walker, Sirnes, |
| Trial | Studied treatment | Control | Patients |
|---|
| Eisenberg, 1985 | Nifedipine 20mgx4 | placebo | patients with nontransmural myocardial infarction | | Bradagan, 1986 | Nifedipine 10mgx4 | placebo | patients with suspected acute myocardial infarction within 6hrs | | Jaffe, 1987 | Nifedipine 6x20mg | placebo | patients with acute myocardial infarction | | Gottlieb, 1988 | Nifedipine 10 to 30mgx4 | placebo | | | Erbel, 1988 | Nifedipine 20mgx3 | placebo | patients with acute myocardial infarction | | Loogna, 1985 | Nifedipine 4x10mg | placebo | patients with acute myocardial infarction within 6 h from onset of symptoms | | TRENT (Wilcox), 1986 | Nifedipine 4x10mg | placebo | patients with suspected myocardial infarction | | Walker, 1988 | Nifedipine 6x10mg for 48hrs | placebo | patients with suspected myocardial infarction within six hours from the onset of chest pain | | Sirnes, 1984 | Nifedipine 5x10mg | placebo | patients with suspected acute myocardial infarction |
| |
| Nifedipine | acute myocardial infarction, in long term studies | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | no data | | cardiac death | no data | | All cause death | 1.05 [0.83 1.32] | p=1.00 | 0 | 1792 | 1 | MI study group, |
| Trial | Studied treatment | Control | Patients |
|---|
| MI study group, 1979 | Nifedipine 3-4x60mg | | |
| |
| Nifedipine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 0.96 [0.71 1.31] | p=1.00 | 0 | 1358 | 1 | SPRINT II, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.87 1.38] | p=1.00 | 0 | 3634 | 2 | SPRINT I, SPRINT II, |
| Trial | Studied treatment | Control | Patients |
|---|
| SPRINT I, 1988 | Nifedipine 10mgx3 | placebo | patient surviving MI 7 and 21 days after admission | | SPRINT II, 1993 | Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months | placebo | men and women with suspected acute MI |
| |
| Nifedipine | post myocardial infarction, in all type of patients | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | no data | | cardiac death | no data | | All cause death | 1.05 [0.83 1.32] | p=1.00 | 0 | 1792 | 1 | MI study group, |
| Trial | Studied treatment | Control | Patients |
|---|
| MI study group, 1979 | Nifedipine 3-4x60mg | | |
| |
| Nifedipine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.92 [0.62 1.36] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | confirmed myocardial infarction | 0.96 [0.71 1.31] | p=1.00 | 0 | 1358 | 1 | SPRINT II, | | cardiac death | 1.01 [0.69 1.50] | p=1.00 | 0 | 2276 | 1 | SPRINT I, | | All cause death | 1.10 [0.87 1.38] | p=1.00 | 0 | 3634 | 2 | SPRINT I, SPRINT II, |
| Trial | Studied treatment | Control | Patients |
|---|
| SPRINT I, 1988 | Nifedipine 10mgx3 | placebo | patient surviving MI 7 and 21 days after admission | | SPRINT II, 1993 | Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months | placebo | men and women with suspected acute MI |
| |
| Verapamil | acute myocardial infarction, in acute short term and post MI studies | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 54 | 1 | Bussman, | | cardiac death | no data | | All cause death | 0.86 [0.02 45.09] | p=1.00 | 0 | 54 | 1 | Bussman, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bussman, 1984 | Verapamil 5 to 10 mg/h IV | no treatment | |
| |
| Verapamil | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3464 | 2 | Crea, Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II, CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6312 | 4 | Crea, DAVIT II, CRIS, Danish study, |
| Trial | Studied treatment | Control | Patients |
|---|
| DAVIT I, 1984 | verapamil 120mgx3 | placebo | | | Crea, 1985 | verapamil 80mgx3 | placebo | patients admitted to the coronary care unit with transmural acute myocardial infarction | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months | placebo | patients <76years with diagnosis of acute MI | | CRIS, 1996 | verapamil retard 360 mg daily | placebo | patients admitted for acute myocardial infarction | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally | placebo | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction |
| |
| Verapamil | acute myocardial infarction, in acute (short term) treatment | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 54 | 1 | Bussman, | | cardiac death | no data | | All cause death | 0.86 [0.02 45.09] | p=1.00 | 0 | 54 | 1 | Bussman, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bussman, 1984 | Verapamil 5 to 10 mg/h IV | no treatment | |
| |
| Verapamil | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 17 | 1 | Crea, | | cardiac death | no data | | All cause death | 0.23 [0.01 5.59] | p=1.00 | 0 | 17 | 1 | Crea, |
| Trial | Studied treatment | Control | Patients |
|---|
| Crea, 1985 | verapamil 80mgx3 | placebo | patients admitted to the coronary care unit with transmural acute myocardial infarction |
| |
| Verapamil | acute myocardial infarction, in long term studies | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3447 | 1 | Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II, CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6295 | 3 | DAVIT II, CRIS, Danish study, |
| Trial | Studied treatment | Control | Patients |
|---|
| DAVIT I, 1984 | verapamil 120mgx3 | placebo | | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months | placebo | patients <76years with diagnosis of acute MI | | CRIS, 1996 | verapamil retard 360 mg daily | placebo | patients admitted for acute myocardial infarction | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally | placebo | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction |
| |
| Verapamil | post myocardial infarction, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3447 | 1 | Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II, CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6295 | 3 | DAVIT II, CRIS, Danish study, |
| Trial | Studied treatment | Control | Patients |
|---|
| DAVIT I, 1984 | verapamil 120mgx3 | placebo | | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months | placebo | patients <76years with diagnosis of acute MI | | CRIS, 1996 | verapamil retard 360 mg daily | placebo | patients admitted for acute myocardial infarction | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally | placebo | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction |
| |
| Amlodipine | heart failure, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Packer, 1991 | amlodipine | | CHD multiple cause, NYHA class II-III | | Smith, 1994 | amlodipine | | CHD multiple cause, NYHA class II-III | | Udelson, 1996 | amlodipine | | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III | | Binkley, 1996 | amlodipine | | CHD multiple cause, NYHA class II-III | | Ghali, 1997 | amlodipine | | CHD multiple cause, NYHA class III-IV |
| |
| Amlodipine | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.92 [0.73 1.16] | p=1.00 | 0 | 1153 | 1 | PRAISE, | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | 0.98 [0.83 1.14] | p=1.00 | 0 | 2805 | 2 | PRAISE, PRAISE II , |
| Trial | Studied treatment | Control | Patients |
|---|
| PRAISE, 1996 | amlodipine 10 mg once daily | placebo | patients with severe chronic heart failure and ejection fractions of less than 30 percent appl | | PRAISE II , 2000 | Amlodipine | placebo | heart failure in non ischemic cardiomyopathy |
| |
| Diltiazem | acute coronary syndrome, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Göbel (Dutch study), 1995 | diltiazem intravenously | glyceryl trinitrate intravenously | patients with unstable angina | | DRS, 1986 | diltiazem 90 mg every six hours up to 14 days | placebo | patients with non-Q-wave myocardial infarct, 24 to 72 hours after the onset of infarction |
| |
| Diltiazem | acute myocardial infarction, in acute short term and post MI studies | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.97 [0.20 4.68] | p=1.00 | 0 | 75 | 1 | Machecourt, | | cardiac death | no data | | All cause death | 0.49 [0.08 2.84] | p=1.00 | 0 | 75 | 1 | Machecourt, |
| Trial | Studied treatment | Control | Patients |
|---|
| Machecourt, 1986 | Diltiazem 360mg IV/24h plus 360mh/24h orally | | |
| |
| Diltiazem | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 34 | 1 | Zannad, | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.01 [0.81 1.26] | p=1.00 | 0 | 3076 | 3 | Gibson, MDPIT, Zannad, |
| Trial | Studied treatment | Control | Patients |
|---|
| Gibson, 1986 | Diltiazem 90mgx4 | placebo | | | MDPIT, 1988 | Diltiazem 60mgx4 | placebo | Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction | | Zannad, 1988 | Diltiazem 10-20mg/h IV, 4x60mg orraly | placebo | |
| |
| Diltiazem | acute myocardial infarction, in acute (short term) treatment | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | 0.97 [0.20 4.68] | p=1.00 | 0 | 75 | 1 | Machecourt, | | cardiac death | no data | | All cause death | 0.49 [0.08 2.84] | p=1.00 | 0 | 75 | 1 | Machecourt, |
| Trial | Studied treatment | Control | Patients |
|---|
| Machecourt, 1986 | Diltiazem 360mg IV/24h plus 360mh/24h orally | | |
| |
| Diltiazem | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 34 | 1 | Zannad, | | cardiac death | no data | | All cause death | 1.21 [0.51 2.84] | p=1.00 | 0 | 610 | 2 | Gibson, Zannad, |
| Trial | Studied treatment | Control | Patients |
|---|
| Gibson, 1986 | Diltiazem 90mgx4 | placebo | | | Zannad, 1988 | Diltiazem 10-20mg/h IV, 4x60mg orraly | placebo | |
| |
| Diltiazem | acute myocardial infarction, in long term studies | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | no data | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.00 [0.79 1.25] | p=1.00 | 0 | 2466 | 1 | MDPIT, |
| Trial | Studied treatment | Control | Patients |
|---|
| MDPIT, 1988 | Diltiazem 60mgx4 | placebo | Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction |
| |
| Diltiazem | heart failure, in all type of patients | vs placebo | hospitalisation for heart failure by 74% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | 0.26 [0.13 0.52] | p=0.04 | 0 | 221 | 1 | Liao , | | All cause death | 0.59 [0.27 1.30] | p=1.00 | 0 | 407 | 2 | Liao , DiDi, |
| Trial | Studied treatment | Control | Patients |
|---|
| Liao , 1998 | diltiazem 30mg twice daily | control (vitamin B1 30mg twice daily) | patients with dilated cardiomyopathy | | DiDi, 1996 | diltiazem 60mg three times daily | placebo | idiopathic dilated cardiomyopathy and LVEF<0.50 |
| |
| Diltiazem | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.85 [0.65 1.13] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | confirmed myocardial infarction | no data | | cardiac death | 1.03 [0.79 1.33] | p=1.00 | 0 | 2466 | 1 | MDPIT, | | All cause death | 1.00 [0.79 1.25] | p=1.00 | 0 | 2466 | 1 | MDPIT, |
| Trial | Studied treatment | Control | Patients |
|---|
| MDPIT, 1988 | Diltiazem 60mgx4 | placebo | Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction |
| |
| Felodipine | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | 1.67 [0.27 10.44] | p=1.00 | 0 | 20 | 1 | Kassis, | | hospitalisation for heart failure | no data | | All cause death | 1.13 [0.69 1.87] | p=1.00 | 0 | 721 | 3 | VHeFT III, Littler, Kassis, |
| Trial | Studied treatment | Control | Patients |
|---|
| VHeFT III, 1997 | felodipine 5mg twice daily | placebo | male patient over 18 years with heart failure | | Kassis, 1987 | felodipine 10 mg twice daily | placebo | patients on conventional therapy for severe CHF | | Littler, 1995 | felodipine extended release 2.5-10mg twice daily (in addition to existing background medication) for 12 weeks | placebo | patients with NYHA class II-III stable congestive heart failure despite treatment with ACE inhibitors, diuretic and digoxin or any combinaison of these drugs | | Kassis, 1990 | felopidine 10 mg BID | placebo | severe congestive heart failure (NYHA class III) |
| |
| Felodipine | | vs enalapril | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Dunselman, 1990 | felodipine 10 mg b.i.d. | enalapril 10 mg b.i.d. | patients with congestive heart failure due to ischaemic heart disease and NYHA class III | | De Vries, 1995 | felodipine 2.5mg twice daily | enalapril 2.5mg twice daily | patients NYHA class II-III with left ventricular ejection fraction <0.4, symptoms of CHD despite therapy with diuretics and digoxin |
| |
| Isradipine | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Van den Toren, 1996 | isradipine up to 5mg 3 times daily | placebo | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III, FE<40% |
| |
| Mibefradil | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | 1.08 [0.90 1.30] | p=1.00 | 0 | 2590 | 1 | MACH 1, | | Coronary death | no data | | hospitalisation for heart failure | 0.85 [0.71 1.02] | p=1.00 | 0 | 2590 | 1 | MACH 1, | | All cause death | 1.10 [0.92 1.31] | p=1.00 | 0 | 2590 | 1 | MACH 1, |
| Trial | Studied treatment | Control | Patients |
|---|
| MACH 1, 2000 | mibefradil titrated up to100mg daily | placebo | Patients with moderate to severe congestive heart failure (NYHA class II to IV and left ventricular fraction ,35%).pj |
| |
| Nicardipine | heart failure, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Gheorghiade, 1991 | nicardipine | | CHD multiple cause, NYHA class III | | Abrams, 1993 | nicardipine | | CHD multiple cause, NYHA class III-IV |
| |
| Nisoldipine | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Gaudron, 1996 | Nisoldipine | placebo | patients with congestive heart failure due to ischaemic heart disease, NYHA class II, FE<=45% | | Rousseau, 1994 | nisoldipine 20 mg once daily | placebo | patients with congestive heart failure due to ischaemic heart disease, NYHA class II |
| |
| Nisoldipine | | vs captopril | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Coronary death | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Schofer, 1990 | nisoldipine (2 X 10 mg) | captopril (3 X 25 mg) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III |
| |
